Company's Profile
Sirtex Medical Limited, a life-sciences company, develops and delivers oncology treatments using novel small particle technology in the Asia-Pacific, Europe, the Middle East, Africa, and North and South America. The company’s principal product is the SIR-Spheres Y-90 resin microspheres, a targeted radioactive treatment for primary and secondary metastatic liver cancer. Sirtex Medical Limited is headquartered in North Sydney, Australia. As of September 20, 2018, Sirtex Medical Limited operates as a subsidiary of CDH Genetech Limited.